Topical application of nebulized human IgG, IgA and IgAM in the lungs of rats and non-human primates

Respiratory Research  
• Research
• Open Access

• Cédric VonarburgEmail authorView ORCID ID profile,
• Marius Loetscher,
• Martin O. Spycher,
• Alain Kropf,
• Marlies Illi,
• Sharon Salmon,
• Sean Roberts,
• Karin Steinfuehrer,
• Ian Campbell,
• Sandra Koernig,
• Joseph Bain,
• Monika Edler,
• Ulrich Baumann,
• Sylvia Miescher,
• Dennis W. Metzger,
• Alexander Schaub,
• Fabian Käsermann and
• Adrian W. Zuercher

Respiratory Research201920:99

https://doi.org/10.1186/s12931-019-1057-3

Abstract

Background

Recurrent and persistent infections are known to affect airways of patients with Primary Immunodeficiency despite appropriate replacement immunoglobulin serum levels. Interestingly, patients with Chronic Obstructive Pulmonary Disease or with non-CF bronchiectasis also show similar susceptibility to such infections. This may be due to the limited availability of immunoglobulins from the systemic circulation in the conductive airways, resulting in local immunodeficiency. Topical application of nebulized plasma-derived immunoglobulins may represent a means to address this deficiency. In this study, we assessed the feasibility of nebulizing plasma-derived immunoglobulins and delivering them into the airways of rats and non-human primates.

Stella Lee, MD: CRSwNP Patients, Before Dupilumab

Source: 

Conjunctivitis in dupilumab clinical trials

Clinical Trial 

 

Open Access

B. Akinlade 

 

E. Guttman‐Yassky 

 

M. de Bruin‐Weller 

 

E.L. Simpson 

 

A. Blauvelt 

 

M.J. Cork 

 

E. Prens 

 

P. Asbell 

 

E. Akpek 

 

J. Corren 

 

C. Bachert 

 

I. Hirano 

 

J. Weyne 

 

A. Korotzer 

 

Z. Chen 

… See all authors 

 

https://doi.org/10.1111/bjd.17869

Summary

Background

Dupilumab blocks the shared receptor component for interleukin (IL)‐4 and IL‐13. It is approved in the U.S.A. for patients aged ≥ 12 years with moderate‐to‐severe atopic dermatitis (AD) uncontrolled by topical prescription medicines or who cannot use topical medicines, for patients in Japan whose AD is uncontrolled with existing therapies, for patients with moderate‐to‐severe AD in Europe who are candidates for systemic therapy and for patients aged ≥ 12 years for maintenance treatment of moderate‐to‐severe asthma uncontrolled with their current medicines. AD trials have reported increased incidence of conjunctivitis for dupilumab vs. placebo.

Genotype-first analysis of a generally healthy population cohort supports genetic testing for diagnosis of hereditary angioedema of unknown cause

• Case report
• Open Access

• Dale L. BodianEmail author,
• Thierry Vilboux and
• Natalie S. Hauser

Allergy, Asthma & Clinical Immunology201915:32

Abstract

Background

Hereditary angioedema (HAE) is a potentially life-threatening group of conditions that is often underdiagnosed or misdiagnosed. As HAE is typically diagnosed by detecting C1 inhibitor deficiency, there is a critical need for methods that can identify affected individuals with normal C1 inhibitor. The recent discovery of associations between PLG K330E and ANGPT1 A119S and HAE of unknown genetic cause (HAE-U), has raised the possibility that genetic evaluation could be used to diagnose HAE-U in patients with unexplained angioedema or non-confirmatory laboratory testing.

Ambulatory Management of Childhood Asthma Using a Novel Self-management Application

Dupilumab side effect in a patient with atopic dermatitis: a case report study

 Biologics: Targets and Therapy » Volume 13

Sakhar S Albader,¹ Abdulmajeed A Alharbi,² Rakan F Alenezi,¹ Fahad M Alsaif<sup>3

1</sup>College of Medicine, King Saud University, Riyadh, Saudi Arabia; ²College of Medicine, Alqassim University, Qassim, Saudi Arabia; ³Division of Dermatology, College of Medicine, King Saud University, Riyadh, Saudi Arabia

Abstract: Atopic dermatitis (eczema) is a common chronic disease that is described as severe itching associated with recurrent eczematous lesions. In 2017 the US Food and Drug Administration approved dupilumab for treatment of adults with moderate to severe atopic dermatitis not well controlled with topical therapies or when other therapies are inadvisable. Dupilumab is a monoclonal antibody that inhibits interleukin-4 (IL-4) and IL-13 signaling by specifically binding to the IL-4R-alpha subunit shared by the IL-4 and IL-13 receptor complexes. There are many adverse effects reported after dupilumab therapy; commonly reported adverse effects include local injection site reactions, conjunctivitis, headache, and nasopharyngitis. Some adverse effects are rare, eg, alopecia areata and cicatricial extropion. We report a new case of a 28-year-old female who experienced face and neck rash after dupilumab injection.

Download Article [PDF]  View Full Text [HTML]

Association of molds and metrological parameters to frequency of severe asthma exacerbation

Allergy, Asthma & Clinical Immunology                 
• Research
• Open Access

• Mona Al-AhmadEmail authorView ORCID ID profile,
• Edin Jusufovic,
• Nermina Arifhodzic,
• Tito Rodriguez and
• Jasmina Nurkic

Allergy, Asthma & Clinical Immunology201915:29

Abstract

Background

Sensitization to airborne molds may be a risk factor for severe asthma and direct cause of asthma exacerbation (AE).

Methods

A prospective, 1-year (April 2016–March 2017) study, done in Kuwait Allergy Centre, investigated the link between AEs with exposure to outdoor molds and the role of meteorological parameters in mold sensitized patients and compared with non-allergic asthma patients who had asthma deterioration.

Sublingual immunotherapy tablet for the treatment of house dust mite allergic rhinitis in Canada: an alternative to minimize treatment costs?

Allergy, Asthma & Clinical Immunology
• Research Open Access

• Anne K. Ellis,
• Rémi Gagnon,
• Eva Hammerby

• and
• Andrea Lau

Allergy, Asthma & Clinical Immunology201915:27

Abstract

Background

A cost-minimization analysis (CMA) was performed to estimate the economic impact of introducing the SQ house dust mite sublingual immunotherapy (SQ HDM SLIT)-tablet marketed as ACARIZAX™ (regulatory approval May 2017) for the treatment of HDM-induced allergic rhinitis in Canada (Ontario and Quebec), where house dust mite subcutaneous immunotherapy (HDM SCIT) is already an available treatment option.

Skin microdialysis: methods, applications and future opportunities—an EAACI position paper

Clinical and Translational Allergy

• Review
• Open Access

• Katrine Y. Baumann,
• Martin K. Church,
• Geraldine F. Clough,
• Sven Roy Quist,
• Martin Schmelz,
• Per Stahl Skov,
• Chris D. Anderson,
• Line Kring Tannert,
• Ana Maria Giménez-Arnau,
• Stefan Frischbutter,
• Jörg Scheffel and
• Marcus MaurerEmail author

Clinical and Translational Allergy20199:24

Abstract

Skin microdialysis (SMD) is a versatile sampling technique that can be used to recover soluble endogenous and exogenous molecules from the extracellular compartment of human skin. Due to its minimally invasive character, SMD can be applied in both clinical and preclinical settings. Despite being available since the 1990s, the technique has still not reached its full potential use as a tool to explore pathophysiological mechanisms of allergic and inflammatory reactions in the skin. Therefore, an EAACI Task Force on SMD was formed to disseminate knowledge about the technique and its many applications. This position paper from the task force provides an overview of the current use of SMD in the investigation of the pathogenesis of chronic inflammatory skin diseases, such as atopic dermatitis, chronic urticaria, psoriasis, and in studies of cutaneous events during type 1 hypersensitivity reactions. Furthermore, this paper covers drug hypersensitivity, UVB-induced- and neurogenic inflammation, and drug penetration investigated by SMD. The aim of this paper is to encourage the use of SMD and to make the technique easily accessible by providing an overview of methodology and applications, supported by standardized operating procedures for SMD in vivo and ex vivo.

Download PDF

Autoimmune Theories of Chronic Spontaneous Urticaria

REVIEW ARTICLE

Front. Immunol., 29 March 2019 | https://doi.org/10.3389/fimmu.2019.00627 

Sonali J. Bracken1, Soman Abraham2,3 and Amanda S. MacLeod3,4*

• 1Department of Internal Medicine, Duke University School of Medicine, Durham, NC, United States
• 2Department of Pathology, Duke University Medical Center, Durham, NC, United States
• 3Department of Immunology, Duke University Medical Center, Durham, NC, United States
• 4Department of Dermatology, Duke University Medical Center, Durham, NC, United States

Urticaria (hives) is a highly prevalent skin disorder that can occur with or without associated angioedema. Chronic spontaneous urticaria (CSU) is a condition which persists for more than 6 weeks in duration and occurs in the absence of an identifiable provoking factor. CSU results from pathogenic activation of mast cells and basophils, which gives rise to the release of proinflammatory mediators that support the generation of urticaria. Several theories have been put forth regarding the pathogenesis of CSU with much evidence pointing toward a potential autoimmune etiology in up to 50% of patients with this condition. In this review, we highlight the evidence surrounding the autoimmune pathogenesis of chronic urticaria including recent data which suggests that CSU may involve contributions from both immunoglobin G (IgG)-specific and immunoglobulin E (IgE)-specific autoantibodies against a vast array of antigens that can span beyond those found on the surface of mast cells and basophils.

Download PDF

World Allergy Congress 2019 : 48 Hours Left to Submit Your Abstract!

48 Hours Left to Submit Your Abstract!     The World Allergy Organization (WAO) and the French Allergy Society (SFA) invite you to submit an abstract for the World Allergy Congress 2019 that will be held in Lyon, France on 12-14 December 2019.   Accepted, and previously unpublished, abstracts will be published in the World Allergy Organization Journal, an internationally recognized journal with an Impact Factor of 5.676.

The following new articles have just been published in Allergy, Asthma & Clinical Immunology

Allergy, Asthma & Clinical Immunology

The following new articles have just been published in Allergy, Asthma & Clinical Immunology CASE REPORT Health effects of diesel engine exhaust emissions exposure (DEEE) can mimic allergic asthma and rhinitis Elopy Sibanda and Nancy Makaza Allergy, Asthma & Clinical Immunology 2019, 15:31 | Published on: 29 April 2019 Full Text | PDF RESEARCH Association of molds and metrological parameters to frequency of severe asthma exacerbation Mona Al-Ahmad, Edin Jusufovic, Nermina Arifhodzic, Tito Rodriguez and Jasmina Nurkic Allergy, Asthma & Clinical Immunology 2019, 15:29 | Published on: 29 April 2019 Full Text | PDF RESEARCH Variants in the IL17 pathway genes are associated with atopic asthma and atopy makers in a South American population Milca de J. Silva, Maria B. R. de Santana, Bruna R. Tosta, Roberta P. Espinheira, Neuza Maria Alcantara-Neves, Maurício L. Barreto, Camila Alexandrina Figueiredo and Ryan dos S. Costa Allergy, Asthma & Clinical Immunology 2019, 15:28 | Published on: 29 April 2019 Full Text | PDF RESEARCH Stability of peripheral blood immune markers in patients with asthma Nami Shrestha Palikhe, Ana-Maria Bosonea, Cheryl Laratta, Vivek Dipak Gandhi, Drew Nahirney, Angela Hillaby, Miranda Bowen, Mohit Bhutani, Irvin Mayers, Lisa Cameron and Harissios Vliagoftis Allergy, Asthma & Clinical Immunology 2019, 15:30 | Published on: 29 April 2019 Full Text | PDF